Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Krispy Kreme Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Krispy Kreme Inc trades at $3.48 (market cap $572.37M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 7.8× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DNUT | |
|---|---|---|
Market Cap | $4.49B | $572.37M |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $4.70 |
52-Week Low | $20.06 | $2.92 |
Enterprise Value | $3.69B | $1.77B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Krispy Kreme (DNUT) trades at $3.32, down 5.41% today, with a bearish technical signal and neutral oscillators. The company reported Q1 2026 EPS of -$0.05, missing expectations, though Q4 2025 and Q3 2025 beat estimates. Revenue for 2025 was $1.52B with a net loss of -$515.77M, reflecting a -33.36% net margin. Analyst consensus is 50% buy, 35.71% hold, and 14.29% sell. Recent news highlights automation efforts and new product launches to attract younger consumers.
The outlook remains challenging with persistent losses and high debt, but strategic pivots to capital-light models and international growth offer potential. Risks include execution missteps and competitive pressures. Investors should weigh turnaround progress against financial instability, with Q2 2026 earnings on August 6, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
